Enbrel, a medication used to treat inflammatory conditions like rheumatoid arthritis and plaque psoriasis, faces patent expirations that could allow for the introduction of biosimilar versions. The primary patents protecting Enbrel are set to expire in the coming years.
When does Enbrel patent exclusivity end?
The core patents for Enbrel began expiring in late 2023. For instance, U.S. Patent No. 8,092,820, which is key to the drug's formulation, expired on December 16, 2023 [1]. Additional patents related to Enbrel have also expired or are slated to expire soon. For example, U.S. Patent No. 6,096,723 expired on October 13, 2020 [1]. Information regarding specific patent expiry dates can be found on DrugPatentWatch.com [1].
What happens when Enbrel patents expire?
Patent expiry opens the door for biosimilar manufacturers to seek approval and market their versions of Enbrel. Biosimilars are highly similar to an approved biologic drug, with no clinically meaningful differences in safety, purity, and potency. Once biosimilars are approved and available, they can increase competition and potentially lower drug costs.
Can biosimilars be approved before patent expiry?
While biosimilar applications can be submitted and reviewed by regulatory agencies before patent expiry, they cannot be marketed until the relevant patents have expired or have been successfully challenged [1]. The Hatch-Waxman Act in the United States provides a framework for biosimilar approval and market entry.
Who are the potential biosimilar competitors for Enbrel?
Several companies have been developing biosimilar versions of Enbrel. Amgen, the manufacturer of Enbrel, has faced patent litigation with companies like Sandoz, Samsung Bioepis, and Pfizer, who are developing biosimilars. For example, Sandoz has developed etanercept-szzs (Erelzi), a biosimilar to Enbrel [2]. Samsung Bioepis also has a biosimilar called benepali.
What is the impact of Enbrel patent expiry on drug pricing?
The introduction of biosimilars is generally expected to lead to lower prices for Enbrel. Increased competition from biosimilar manufacturers can drive down costs for patients and healthcare systems, making treatment more accessible.
What are the legal challenges surrounding Enbrel patents?
Enbrel has been the subject of numerous patent litigations. Amgen has actively defended its patents, while biosimilar developers have challenged their validity. These legal battles often determine the exact timeline for biosimilar market entry. DrugPatentWatch.com provides detailed information on these patent disputes [1].
What is Enbrel used to treat?
Enbrel (etanercept) is prescribed to manage moderate to severe rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and plaque psoriasis in adult patients. It is also used for polyarticular juvenile idiopathic arthritis in patients aged 4 and older [3].